Company Overview
M. K. Proteins Limited engages in the manufactures and trades in vegetable refined oil and by-products in India. It offers rice bran, sunflower, cotton seed, soya bean, palm, canola, and rice bran bleached oils. The company also provides by-products, including rice bran fatty acid oils, rice bran waxes, gums, and spent earth; imports, processes, and sells crude oils; and trades in edible and non-edible oils. M. K. Proteins Limited was incorporated in 2012 and is based in Ambala, India.
Why Investors Should Care
Trades at a P/E of 22.3, below the sector median of 23.6.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹382.88 Cr (+43.0% YoY); net profit ₹6.83 Cr.
- Trailing 12 Months Year-on-year growth — revenue +43.0%, earnings -18.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.7%, profit CAGR -14.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.74% |
| 1 Year: | 43.02% |
Compounded Profit Growth
| 5 Years: | -14.52% |
| 1 Year: | -18.68% |
Stock Price Performance
| 1 Year: | -40.62% |
| 6 Months: | -17.96% |
| 3 Months: | -18.29% |
| 1 Month: | -2.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.74 · Neutral
P/E of 22.33 is below the sector median of 23.57 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -14.5% CAGR over 5 years.
- Trading 47.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MKPL M. K. Proteins Limited NSE | 4.02 | 22.33 | ₹150.90 Cr | 0.00% | 14.29% | 8.95% | 6.74% | -14.52% |
| 2 | HINDUNILVR Hindustan Unilever Limited NIFTY50NSE | 1,973.40 | 30.83 | ₹4.64 L Cr | 2.12% | 22.15% | 30.86% | 2.31% | 14.12% |
| 3 | ITC ITC Limited NIFTY50NSE | 264.10 | 16.00 | ₹3.31 L Cr | 5.60% | 36.47% | 28.53% | 3.65% | 2.54% |
| 4 | NESTLEIND Nestlé India Limited NIFTY50NSE | 1,410.50 | 84.82 | ₹2.72 L Cr | 0.78% | 62.44% | 79.99% | 17.01% | 23.05% |
| 5 | DMART Avenue Supermarts Limited NSE | 3,770.00 | 82.62 | ₹2.46 L Cr | 0.00% | 16.41% | 12.14% | 17.14% | 7.69% |
| 6 | VBL Varun Beverages Limited NSE | 407.60 | 45.39 | ₹1.38 L Cr | 0.45% | 19.44% | 15.51% | 17.26% | 26.57% |
| 7 | BRITANNIA Britannia Industries Limited NSE | 5,101.50 | 48.50 | ₹1.23 L Cr | 1.67% | 61.21% | 49.61% | 5.66% | 2.95% |
| 8 | UNITDSPR UNITED SPIRITS LIMITED NSE | 1,471.70 | 56.84 | ₹1.07 L Cr | 1.11% | 25.49% | 20.53% | 5.56% | 17.36% |
| 9 | MARICO Marico Limited NIFTY_MIDNSE | 815.15 | 59.98 | ₹1.06 L Cr | 0.47% | 38.75% | 41.85% | 11.82% | 10.61% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 137.20 Cr | 114.95 Cr | 32.43 Cr | 89.56 Cr | 145.94 Cr |
| Cost of Revenue | - | 131.72 Cr | 106.06 Cr | 30.85 Cr | 86.35 Cr | 142.33 Cr |
| Gross Profit | - | 5.48 Cr | 8.89 Cr | 1.58 Cr | 3.21 Cr | 3.61 Cr |
| Operating Expenses | - | 91.34 L | 3.48 Cr | 64.08 L | 96.52 L | 1.22 Cr |
| Operating Income | - | 4.57 Cr | 5.41 Cr | 94.00 L | 2.24 Cr | 2.39 Cr |
| EBITDA | - | 4.68 Cr | 5.51 Cr | 1.17 Cr | 2.38 Cr | 2.62 Cr |
| Interest Expense | - | 67.44 L | 70.16 L | 6.45 L | 29.56 L | 79.03 L |
| Pretax Income | - | 3.92 Cr | 4.71 Cr | 99.98 L | 1.97 Cr | 1.72 Cr |
| Tax Provision | - | 1.12 Cr | 1.19 Cr | 25.31 L | 53.55 L | 57.91 L |
| Net Income | - | 2.80 Cr | 3.51 Cr | 74.67 L | 1.43 Cr | 1.14 Cr |
| Diluted EPS | - | 0.07 | 0.09 | 0.02 | 0.04 | 0.03 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 314.86 Cr | 245.57 Cr | 267.71 Cr | 382.88 Cr |
| Cost of Revenue | - | 294.37 Cr | 223.92 Cr | 252.53 Cr | 368.43 Cr |
| Gross Profit | - | 20.49 Cr | 21.65 Cr | 15.18 Cr | 14.45 Cr |
| Operating Expenses | - | 3.69 Cr | 5.19 Cr | 3.10 Cr | 3.46 Cr |
| Operating Income | - | 16.81 Cr | 16.46 Cr | 12.08 Cr | 10.98 Cr |
| EBITDA | - | 17.65 Cr | 17.06 Cr | 12.91 Cr | 11.68 Cr |
| Interest Expense | - | 1.84 Cr | 1.07 Cr | 1.10 Cr | 1.85 Cr |
| Pretax Income | - | 14.99 Cr | 15.47 Cr | 11.45 Cr | 9.39 Cr |
| Tax Provision | - | 4.06 Cr | 4.26 Cr | 3.05 Cr | 2.56 Cr |
| Net Income | - | 10.93 Cr | 11.21 Cr | 8.40 Cr | 6.83 Cr |
| Diluted EPS | - | 0.29 | 0.30 | 0.22 | 0.18 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 103.22 Cr | 96.25 Cr | 130.57 Cr | 131.20 Cr |
| Current Assets | - | 98.58 Cr | 85.83 Cr | 118.52 Cr | 118.23 Cr |
| Cash & Equivalents | - | 6.25 L | 9.23 L | 3.38 L | 43.82 L |
| Inventory | - | 71.20 Cr | 79.27 Cr | 111.32 Cr | 109.78 Cr |
| Receivables | - | 16.06 Cr | 3.57 Cr | 1.40 Cr | 2.11 Cr |
| Total Liabilities | - | 53.36 Cr | 35.17 Cr | 61.10 Cr | 54.90 Cr |
| Current Liabilities | - | 49.63 Cr | 33.96 Cr | 59.00 Cr | 52.54 Cr |
| Long Term Debt | - | 2.54 Cr | 0 | 83.04 L | 1.05 Cr |
| Total Debt | - | 45.53 Cr | 20.08 Cr | 38.72 Cr | 37.14 Cr |
| Total Equity | - | 49.86 Cr | 61.08 Cr | 69.47 Cr | 76.30 Cr |
| Shares Outstanding | - | 37.54 Cr | 37.54 Cr | 37.54 Cr | 37.54 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.87 Cr | 32.42 Cr | -16.13 Cr | 5.43 Cr |
| Investing Cash Flow | - | 1.34 L | -5.88 Cr | -1.48 Cr | -1.60 Cr |
| Financing Cash Flow | - | 5.92 Cr | -26.51 Cr | 17.55 Cr | -3.43 Cr |
| Capital Expenditure | - | -72,052 | -5.90 Cr | -2.22 Cr | -1.90 Cr |
| Free Cash Flow | - | -5.88 Cr | 26.51 Cr | -18.35 Cr | 3.54 Cr |
| Net Change in Cash | - | 5.58 L | 2.98 L | -5.85 L | 40.44 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 6.5% | 8.8% | 5.7% | 3.8% |
| Operating Margin % | - | 5.3% | 6.7% | 4.5% | 2.9% |
| Net Margin % | - | 3.5% | 4.6% | 3.1% | 1.8% |
| ROE % | - | 21.9% | 18.4% | 12.1% | 9.0% |
| ROCE % | - | 31.4% | 26.4% | 16.9% | 14.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MKPL
Unpleasant Surprises Could Be In Store For M. K. Proteins Limited's (NSE:MKPL) Shares - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNalhHbUQ1bjZ1VlEzSHlsWTlDaUREYkx0amhEcXhrUFFpNzRLc05DMGhUdEdjUHB5dzJqMXg4SWNmUkd6ZklCX3FWdG9wVEZER01jckhxQnMxVHJzVlpFVHF3Z21ZcngzSEVyc0NaNW9iS3VBUGNFOWw2UjVZRjBSMVVLSUdlVG5DN1B5eU…
M K Proteins Q2 FY2026 Earnings: Revenue Surges 43% YoY, But Stock Slips - Margin Compression Risk - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOV2ZYUC1xTmZ1dzU3Q2ZVSDJINm1tTUoxOVlCaFR1MmpyUWt3VGxzWmhKUG5xVndHU3JMUWdvNHJJU1AyR3NySGwtSTZSUkZ4UHh6b0p3bVBKNWdHbmhWQjNDekRSSVB1UmNKVThVbV8ySVZqMVR4ZWJhWGdxeU1iTFdfNGRSXzBnSXNpd1…
M K Proteins Share Price Target 2026: Bull Case Rs 5.00, Bear Cas - Univest
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5UQ0hTRHpyd2Q0Wi1wNnR5WllZeXU1blQzMlBsWERWMnh3cU9TYnBTOGJtLXpiczZoTGRXRThBOUs2VVhXUUdUY1ZrRHphdXFwdGtUSVFMWXRXMGdHd1lrcHc1Z2QyRzRUUVhCQS1R?oc=5" target="_blank">M K Proteins Share …
MKPL Q2 2026 Earnings: Robust Revenue Growth of 43% YoY Despite Stock Weakness - Management Guidance Update - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQN1JUajJWc0hIaUpCd2hod2FGX05FRzJYWXJ4TTRsQ2xqNnZBM0RmeFpXMm5RS3dHWC1peW5OQ0pqX1hpazZsYmdEOFNrMzdSTG9EeGVycEFNMEo5S1I0amJ2RVZVTzlKQ254dWNMeUk1cVpyZVczcTNaa1VGSU8tUnVaT0pFbTY0cENpQm…
M K Proteins Declines Over 2%: Testing Key Support at ₹4.57 - Order Block - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPdGd1Q19UUFdYMnlEeXVsWjY4X0xITUZ1SVdzRnN0Yl9PSzRjaUxPSC13dXJiZUR2TGlXVDZIbWEzSUVnVWg3aWRxUy1TRUpFRjZNNmdsMXNQdjhIUTN4a21SSVdoRUR3QXJPaHo0bFJ1WUg2SzBaemdXWVVoVkcybzB2bHZ0LW8tN253d2…
RBS Stock Price and Chart — NSE:RBS - TradingView
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE1lU21GQlNzc045YlZMUHBVMGl3aWZKMEdFQm5JalpZUmhuSk9BaWRtQ19lbHV0dTRWOG1pM01YcnlibzlHcG91a2lfVmlneDVvWU04WU5Gdw?oc=5" target="_blank">RBS Stock Price and Chart — NSE:RBS</a> &nbs…
MKPL — Frequently Asked Questions
What is the current share price of M. K. Proteins Limited (MKPL)?
As of 2026-09-08 04:53 IST, M. K. Proteins Limited (MKPL) trades at ₹4.02 on NSE. Its 52-week range is ₹3.87 to ₹7.61.
What is the market capitalisation of MKPL?
M. K. Proteins Limited (MKPL) has a market capitalisation of ₹150.90 Cr on NSE.
What is the P/E ratio of MKPL?
MKPL trades at a trailing price-to-earnings (P/E) ratio of 22.33. The industry average P/E is 23.57. Its price-to-book (P/B) ratio is 2.09.
What is the return on equity (ROE) of MKPL?
MKPL has a return on equity (ROE) of 8.95%. Its return on capital employed (ROCE) is 14.29%.
Is MKPL a good stock to buy?
This page provides a data-driven analysis of M. K. Proteins Limited (MKPL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.